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Abstract. Tau proteins and amyloid- (A) peptides are the current recognized cerebrospinal fluid (CSF) biomarkers used as an
aid in the diagnosis of Alzheimer’s disease (AD). However, there is no consensus on their clinical use due to non-qualified cut-off
values, probably related to the observed high pre-analytical and analytical variability. Standardized pre-analytical protocols have
therefore been proposed. Importantly, these recommend the use of polypropylene collection/sampling tubes while, to date, no
broad comparison of these types of tubes has been conducted. In this study, we first compared, as part of a real clinical workflow,
the impact of four different collection tubes on the CSF concentration of A peptides (A42, A40) and total (hTau) and phospho-
rylated (P-Tau181P) tau proteins measured using routine ELISA kits. We then extended this study to 11 polypropylene tubes used
by different clinical laboratories, and investigated their plastic polymer composition using differential scanning calorimetry and
Fourier Transformed Infrared spectroscopy. Significant concentration variations linked solely to the use of different types of tubes
were observed. This was particularly marked for A peptides, with >50% disparity occurring in less than five minutes. Polymer
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composition analysis revealed that most polypropylene tubes were in fact copolymers with at least polyethylene. There was no
clear correlation between tube composition and pre-analytical behavior. Our results show that the use of polypropylene tubes
does not guarantee satisfactory pre-analytical behavior. They also point to collection/sampling tubes being a major pre-analytical
source of variability that could impact the significance of AD biological diagnosis.
Keywords: Alzheimer’s disease, cerebrospinal fluid, collection tubes, standardization
INTRODUCTION
Total tau protein (hTau), its phosphorylated iso-
form at position 181 (p-Tau181P), and amyloid- (A)
peptides (A42 and A40) are the current accepted
cerebrospinal fluid (CSF) biomarkers used as an aid
in the diagnosis of Alzheimer’s disease (AD) [1–5].
They help characterize atypical phenotypes, stratify
patients in clinical trials, and predict AD conversion
in prodromal forms [4, 6, 7]. Due notably to important
between-center variability [2, 8, 9], there is no consen-
sus on their use and their cut-off values to define a CSF
AD signature. Investigation of pre-analytical events
affecting the levels of these biomarkers identified delay
of processing, storage in different types of tubes,
volume per tube, dilution with detergent-containing
buffer, plasma contamination, and heat treatment as
significant factors [10–13].
To minimize pre-analytical and analytical errors,
standardized operating procedures have been proposed
[8, 10, 11]. Importantly, they all recommend the use of
polypropylene tubes instead of polystyrene or glass.
However, only a descriptive study on influence of col-
lection tubes onto the CSF A42 was conducted [14]. In
a recent letter we reported major differences between
collection tubes [15]. Here, we significantly extended
this initial study. We completed the comparison in a
real clinical workflow using four different collection
tubes. We also extended our study of 11 polypropy-
lene tubes, looking at their biomarker performance in
relation with their plastic polymer composition.
Our results show that the use of polypropylene tubes
does not guarantee satisfactory pre-analytical behavior.
They also point to collection/sampling tubes being a
major pre-analytical source of variability that could
impact the significance of AD biological diagnosis.
MATERIALS AND METHODS
Study participants
Samples originated from biobanks generated in
two French Clinical and Research Memory Centres
(CMRRs) specialized in the care of cognitive disor-
ders based in Lyon and Montpellier. Recruited patients
gave their written informed consent to participate in the
biobanks (registered # DC-2008-417). As the focus
of this study was analytical, samples were selected
to cover the different neurochemical situations cor-
responding to different diagnoses, and with variable
concentrations of biomarkers (Fig. 1).
CSF sampling and analysis
In a first series of experiments (Figs. 1 and 2),
CSF from 12 patients was collected directly in four
different types of tubes (2 mL per tube): ST-PP (Sarst-
edt, 10 mL, polypropylene, ref. 62.610.201); HE-PS
(Fisher Scientific hemolysis tube, 5 mL, polystyrene,
ref. W1773X); BD-PE (Becton Dickinson, 14 mL,
polystyrene, ref. 352095), and BD-PP (Becton Dick-
inson, 15 mL, polypropylene, ref. 352096). Collection
tubes were transported on ice to the laboratory and pro-
cessed immediately by centrifugation (10 min, 1000 g).
Samples were divided into 0.5 mL aliquots in
polypropylene Eppendorf tubes (Protein LoBind, ref:
0030108.116.), stored at −80◦C (less than 6 month),
and thawed immediately before quantification. In some
cases (Fig. 2A, B), freshly thawed samples were dis-
tributed in ST-PP tubes for the indicated period of time
at 2–8◦C, or were supplemented with human albumin
for the indicated final concentrations and kept for 1 h
in ST-PP tubes before measurement.
In a second series of experiments (Fig. 3, Tables 2),
six non-hemorrhagic CSF samples were collected
directly in the tube J (Table 1), transported in less than
15 min to the laboratory and processed immediately
by centrifugation (10 min, 1000 g). After homogeniza-
tion, 300 l of the supernatant was distributed in every
one of the 11 tubes (see Table 1 for description of
tubes) and left for 15 min (T1) or 24 h (T2) at 2–8◦C.
They were then stored at −80◦C and thawed before
immediate quantification.
CSF A42, A40, hTau, and p-Tau181P concentra-
tions were measured using standardized commercially
available INNOTEST®/IBL sandwich ELISA tests
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Fig. 1. Individual AD biomarker results from four different tube types. CSF from twelve patients was collected in four different types of tubes:
BD-PP, ST-PP, BD-PE, and HE-PS. After CSF processing, CSF A42, hTau, p-Tau181P, and A40 were measured using commercially available
ELISA tests. For A40 one sample is missing. Note: results are expressed as the mean of two values. Variability between most sample duplicates
was in the range of the intra-assay CVs (from 2 to 8%). Some duplicates corresponding to low values were between 8 and 15%. Statistical
analysis showed that the four tubes all differs (p-values below 0.05) for CSF A42 and A40. For hTau, only BD-PE differs from BD-PP and
ST-PP while for p-Tau181P, HE-PS differs from the tree other tubes. A, amyloid- protein; hTau, total Tau protein; p-Tau181P, Tau protein
phosphorylated at position 181.
according to the supplier’s instructions (Innogenetics,
Ghent, Belgium). To reduce variability, the analysis
of each series was performed within same experiment
using the same batch of kits. Intra-assays CVs were
<5% for As and p-Tau181P, and <8% for hTau.
Statistical analyses
Statistical analyses were performed and graphs pre-
pared using XLSTAT and MedCalc (7.3) software.
Graphical results were presented as medians and
interquartile ranges. The impact of tube type was
assessed using a non-parametric test on the percentage
of concentration deviation for each tube to the average
concentration value for each CSF sample. A Kruskal-
Wallis test was used for comparison of k samples with a
significance level set at 5%. The tubes were compared
two by two with a bilateral test using the Conover-Iman
procedure.
Tube analysis
Physical analysis of the tubes was performed using
two methods [16]. Differential scanning calorimetry,
which is a measurement of a phase change of the
material, those phase changes being characteristic for a
material; melting points were measured and compared
to polyolefin references. Fourier Transformed Infrared
spectroscopy measures the absorption by a sample of
polychromatic radiation in the infrared domain, this
absorption being characteristic of the chemical groups
present in the sample. Thus, the spectrum obtained is
specific to the sample’s material or to the material fam-
ily. The spectra were acquired in reflexion mode giving
a surface analysis with a probe depth of 1 to 5 m.
RESULTS
To investigate pre-analytical variations linked solely
to sampling tubes, CSF samples from 12 patients
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Fig. 2. Median AD biomarker results using four different tube types, along with the effect of time delay and protein concentrations on the
results (in %). A) CSF from twelve patients was collected in four different types of tubes: BD-PP, ST-PP, BD-PE. and HE-PS. CSF A42, hTau,
p-Tau181P, and A40, were measured using commercially available ELISA tests (Fig. 1). For each individual sample, measured concentrations
were converted as a percentage of the mean of the values obtained in the four tubes. Results are presented as medians and interquartile ranges.
B) Four freshly thawed CSF samples with protein content ranging from 0.4 to 0.6 g/L were supplemented with human albumin to raise their
protein concentration by 0, 0.5, 1.0, and 1.5 g/L. These samples were then distributed in ST-PP tubes and left for 1 h at 2–8◦C before A42
measurement. The graph reports the percentage concentration remaining of the initial A42 values. C) Four freshly thawed CSF samples were
distributed in ST-PP tubes for the indicated period of time at 2–8◦C. The graph reports the percentage concentration remaining of the initial
A42 values.
enrolled in an ethically approved study were directly
(from the lumbar puncture needle) collected in four
different types of tubes: two polypropylene tubes, one
polystyrene tube, and one polyethylene tube. hTau,
p-Tau181P, A42, and A40 concentrations were then
measured in parallel (Fig. 1).
When the results were expressed as a percentage
of the median value obtain in the four tubes (Fig. 2),
biomarkers concentration showed major variations that
were significantly different in many cases in particu-
lar for A peptides (Fig. 1). Median values for A42
peptides were for example of 80%, 137%, 81%, and
99% in BD-PP, ST-PP, BD-PE, and HE-PS tubes,
respectively. In individual patient samples (Fig. 1),
this effect was present over the whole range of A
values. These data confirmed and extended previous
observation by Pica-Mendez et al. [14].
In summary, much higher A42 and A40 concen-
trations were observed in ST-PP tubes compared to
the other tubes. Statistical differences between non
polypropylene tubes were also observed for hTau (HE-
PS) and p-Tau181P (BD-PE) (Fig. 1). This clearly
illustrated that each tube has its own pre-analytical
property.
In contrast with common knowledge and recom-
mendations, it was clear that using polypropylene
tubes did not always result in optimal pre-analytical
behavior. Importantly, the type of tube used for the
same patient could dramatically change the interpre-
tation of the biomarker results, leading therefore to
possible AD misdiagnosis (see individual concentra-
tion values on Fig. 1). hTau and p-Tau181P were,
however, less affected by the type of tubes, confirming
the importance of evaluating A peptides concentra-
tion in combination with these biomarkers.
To further explain the role of collection tubes on
resulting biomarker values, we selected 11 different
commercially available polypropylene collection tubes
(Table 1), some of them being used by different clini-
cal teams in the AD field. We performed an evaluation
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Fig. 3. Effect of time delay on median AD biomarker results from 11 different tube types (in %). After collection in one tube (J, Table 1) and
centrifugation, six CSF supernatants samples were homogenized and distributed into 11 different tubes (A to K, see Table 1) and left at 2–8◦C for
15 min (T1) or for 24 h (T2) before A42, hTau, and p-Tau181P were measured using commercially available ELISA tests. For each individual
sample, the measured concentrations were converted as a percentage of the mean of the values obtained in the 11 tubes. Results are presented
as medians and interquartile ranges. Statistical analysis showed no differences (p-values below 0.05) between T1 and T2 in the 11 tubes. A,
amyloid- protein; hTau, total Tau protein; p-Tau181P, Tau protein phosphorylated at position 181.
Table 1
Impact of polypropylene collection tubes on AD biomarkers and surface polymer composition analysis using differential scanning calorimetry
and Fourier Transformed Infrared spectroscopy
Tube Provider Catalog numbers Vol (mL) Peak maximum (◦C) Peaks super-position Identification
A Greiner 18 82 80 15 151.61 2 PP-PE copolymer
B Greiner 18 82 81 15 150.75 2 PP-PE copolymer
C Deltalab 401402 12 149.99 2 PP-PE copolymer
D Evergreen 222-3529-G8D 30 15.32 2 PP-PE copolymer
E CML TC15PP 15 150.39 2 PP-PE copolymer
F Sarstedt 629.924.284 10 149.83 3 PP-PE +?
G Sarstedt 62.610.201 10 150.16 3 PP-PE +?
H Falcon BD 35 2006 14 150.54 2 PP-PE copolymer
I Nalgene 34 28 05 2 151.63 3 PP-PE +?
J Falcon BD 35 2096 15 150.75 2 PP-PE copolymer
K Gosselin TK75-085 5 168.25 1 PP
Six CSF supernatants of freshly collected samples were distributed in to the 11 tubes for 15 min and A42, hTau, and p-Tau181P were measured
using commercially available ELISA tests. For each individual sample, the measured concentrations were converted as a percentage of the mean
of the values obtained in the 11 tubes. The median of the different percentage are reported in the table. PP, polypropylene; PE, polyethylene.
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Table 2
Statistical differences between values in the 11 tubes (A to K, see Table 1 and Fig. 3)
A1-42 A B C D E F G H I J K
A 1 0.429 <0.0001 <0.001 0.159 0.448 <0.0001 0.029 <0.0001 0.003 0.001
B 1 <0.0001 0.003 0.531 0.124 <0.0001 0.154 <0.0001 <0.001 <0.0001
C 1 <0.0001 <0.0001 <0.0001 0.064 <0.0001 0.895 0.022 0.051
D 1 0.018 <0.0001 <0.0001 0.109 <0.0001 <0.0001 <0.0001
E 1 0.033 <0.0001 0.419 <0.0001 <0.0001 <0.0001
F 1 <0.0001 0.004 <0.0001 0.026 0.010
G 1 <0.0001 0.084 <0.0001 <0.001
H 1 <0.0001 <0.0001 <0.0001
I 1 0.016 0.038
J 1 0.716
K 1
hTau
A 1 0.197 0.414 0.106 0.962 0.035 0.166 0.314 0.797 0.035 0.087
B 1 0.038 0.736 0.181 0.396 0.923 0.773 0.299 0.396 0.665
C 1 0.017 0.442 0.004 0.030 0.071 0.285 0.004 0.013
D 1 0.096 0.608 0.810 0.532 0.171 0.608 0.923
E 1 0.031 0.152 0.292 0.760 0.031 0.079
F 1 0.452 0.257 0.062 1.000 0.677
G 1 0.700 0.257 0.452 0.736
H 1 0.452 0.257 0.471
I 1 0.062 0.144
J 1 0.677
K 1
pTau
A 1 0.510 0.211 0.748 0.600 0.355 0.043 0.267 0.070 0.741 0.046
B 1 0.551 0.344 0.916 0.789 0.165 0.648 0.241 0.741 0.175
C 1 0.132 0.501 0.741 0.424 0.887 0.561 0.355 0.442
D 1 0.419 0.231 0.026 0.169 0.042 0.525 0.027
E 1 0.719 0.154 0.590 0.222 0.834 0.162
F 1 0.260 0.850 0.363 0.551 0.273
G 1 0.347 0.826 0.088 0.975
H 1 0.470 0.433 0.363
I 1 0.135 0.850
J 1 0.094
K 1
p-values are reported, values below 0.05 are in bold italics.
of their impact on the three classical AD biomarkers,
as well as carrying out a surface polymer composi-
tion analysis using differential scanning calorimetry
and Fourier Transformed Infrared spectroscopy. This
revealed surprising results with only one tube consist-
ing of pure polypropylene, the others being copolymers
with at least polyethylene; even-though they were all
labeled as polypropylene (Table 1). Regulations in
fact allow companies to label tubes as being purely
polypropylene even in the presence of other polymers
or surface treatment. Incidentally, the exact polymer
composition of the different tubes was not disclosed
by most of the commercial providers.
Using a series of fresh (unfrozen) CSF samples
from 6 patients, we then distributed them between the
11 tubes and waited 15 min (T1) or 24 h (T2) before
processing the samples using the same analytical con-
ditions (Table 2). This revealed significant differences
between tubes (Table 2) with maximum median varia-
tions of −48%/+31%, −8%/+8%, and −4%/+6%, for
A42, hTau, and p-Tau181P, respectively.
When hTau and p-Tau181P were in the range of
acceptable and observed analytical variations for these
biomarkers, differences in A42 concentrations clearly
exceeded them. The effect was present after 15 min
(T1), and an additional 24 h (T2) incubation time
at 2–8◦C did not significantly change these values
(Fig. 3).
Adsorption of the biomarkers on the tube sur-
face was the most likely explanation for this “tube
effect” [17]. This explanation is consistent with pre-
vious unpublished observations suggesting that CSF
biomarker levels in samples with high protein content
(>1.5 g/L) were not changed by the type of collec-
tion tube, especially in comparison with samples with
low protein content. To confirm this observation, we
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confirmed that artificially raising the protein content
of CSF samples resulted in a disappearance of the tube
effect (Fig. 1B). This was also coherent with the time
course of this effect that was tested in the tube with
the apparent higher A values (ST-PP, Fig. 1C). This
experiment revealed a 20% decrease in A peptides
concentration as early as 5 min after contact with the
tube. This means that when CSF is in contact with
a tube, A peptide values drop almost immediately,
and this effect is iterative (values drops again when
put in a new tube; not shown). Importantly, after these
first 5 min, the impact of additional time (24 and 48 h),
mimicking a pre-analytical delay, was minimal and not
significant up to 48 h (Figs. 1C and 3).
Surprisingly, the pure polypropylene tube (tube K)
did not give the best results and differences between
tubes suggested that additional surface treatment could
also change the adsorption properties of the tubes.
DISCUSSION
The high pre-analytical sensibility of A to different
polymer/plastic surfaces is an important observation to
take into account. Transfer of CSF in to different tubes
during processing or storage can result in a 20% to
60% decrease in measured concentrations. In addition,
analytical protocols often contain intermediate steps
involving transfer of CSF samples into new tubes or
plates, resulting in possible errors. This is true, not only
for A42, but also for other A peptides (A40, A38,
not shown), which are of interest for the diagnosis of
other neurological diseases [18]. Selection of collec-
tion tubes that would preserve the best A peptides
content would therefore make sense.
Adsorption of these analytes to the tube walls
is the most likely explanation for these phenom-
ena. An interesting trend was observed since some
tubes that performed better for p-Tau181P were the
worst for A42 (tubes D and A). This suggests that
the hydrophilic/hydrophobic balance of the analytes
plays an important role in this phenomenon: the more
hydrophobic A42 peptide is greatly adsorbed by some
of the tubes. On the other hand, probably due to its
high content in anionic phosphate groups, p-Tau181P
which is more hydrophilic, is less adsorbed by the
tubes which adsorbed the A42 protein. Hydrophilicity
due to the polymer surface composition is an impor-
tant point in understanding the adsorption of proteins
but other parameters may affect this absorption such
as the polymer surface charge in regard with the iso-
electric point of the protein, or the surface roughness
[16, 19, 20]. It has been shown that changing both
the hydrophilicity and the charge of the surface may
lead to great improvement in the protein recovery [21]
underlying the fact that the tube composition and its
possible surface treatment is a key parameter in protein
adsorption.
In summary, our data indicated that the pre-
analytical impact of sampling/processing tubes has
to be particularly well optimized and harmonized for
multi-site studies and for the definition of relevant
and worldwide AD biomarker cut-off values. One way
to go is probably to define a consensus protocol that
specifically links cut-off values to given sampling tubes
and handling/analytical protocols.
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